BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
71.41 (USD) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | BioMarin Pharmaceutical Inc. |
Symbool | BMRN |
Munteenheid | USD |
Prijs | 71.41 |
Beurswaarde | 13,595,250,030 |
Dividendpercentage | 0% |
52-weken bereik | 68.83 - 99.56 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jean-Jacques Bienaime M.B.A., MBA |
Website | https://www.biomarin.com |
An error occurred while fetching data.
Over BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)